Literature DB >> 7589098

Interleukin-4 inhibits kappa light chain expression and NF kappa B activation but not I kappa B alpha degradation in 70Z/3 murine pre-B cells.

C J Clarke1, D A Taylor-Fishwick, A Hales, Y Chernajovsky, K Sugamura, M Feldmann, B M Foxwell.   

Abstract

The murine pre-B cell line 70Z/3 responds to lipopolysaccharide by up-regulating the surface expression of kappa (kappa) light chain through activation of the transcription factor NF kappa B. Interleukin-4 (IL-4), a T cell cytokine, is a known inhibitor of some LPS-mediated events. We investigated whether IL-4 could inhibit the up-regulation of kappa light chain and activation of NF kappa B by LPS in 70Z/3. IL-4 partially inhibited both the LPS-induced expression of kappa light chain and also the activation of NF kappa B as judged by an NF kappa B reporter gene assay. Additionally, electrophoretic mobility shift assays confirmed this effect on LPS-induced NF kappa B DNA binding activity in the nucleus. Surprisingly, proteolytic degradation of I kappa B alpha (MAD3), a prerequisite for NF kappa B activation, was unaffected by IL-4, implying that this cytokine inhibits some subsequent undefined event in the activation of NF kappa B. IL-4 was also found partially to inhibit NF kappa B activity induced by tumor necrosis factor-alpha (TNF-alpha) and interleukin-1-beta (IL-1 beta). These results indicate that there may be a common mechanism for the well-documented anti-inflammatory effects of IL-4 and that this mechanism involves the transcription factor NF kappa B.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589098     DOI: 10.1002/eji.1830251037

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant.

Authors:  E Andreakos; R O Williams; J Wales; B M Foxwell; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-13       Impact factor: 11.205

2.  NF-κB signaling participates in both RANKL- and IL-4-induced macrophage fusion: receptor cross-talk leads to alterations in NF-κB pathways.

Authors:  Minjun Yu; Xiulan Qi; Jose L Moreno; Donna L Farber; Achsah D Keegan
Journal:  J Immunol       Date:  2011-07-06       Impact factor: 5.422

3.  Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells.

Authors:  T Ichiyama; M Nishikawa; T Yoshitomi; S Hasegawa; T Matsubara; T Hayashi; S Furukawa
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

4.  STAT6 Inhibits TGF-beta1-mediated Foxp3 induction through direct binding to the Foxp3 promoter, which is reverted by retinoic acid receptor.

Authors:  Hiromi Takaki; Kenji Ichiyama; Keiko Koga; Takatoshi Chinen; Giichi Takaesu; Yuki Sugiyama; Shigeaki Kato; Akihiko Yoshimura; Takashi Kobayashi
Journal:  J Biol Chem       Date:  2008-04-09       Impact factor: 5.157

5.  Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators.

Authors:  J Bondeson; B Foxwell; F Brennan; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

6.  Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent.

Authors:  B Foxwell; K Browne; J Bondeson; C Clarke; R de Martin; F Brennan; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.